DFine announces full commercial distribution of the Star Tumor Ablation System in USA


DFine has announced the full commercial US launch of the Star Tumor Ablation System used in the palliative treatment of metastatic spinal tumours.

The Star Tumor Ablation System combines controlled access to the vertebral body with controlled percutaneous radiofrequency ablation (t-RFA) energy delivery to create a controlled radiofrequency ablation zone. This offers physicians the ability to reduce the size and effect of metastatic spinal tumours in a single, minimally invasive (t-RFA) procedure.

“The full commercial launch represents a key milestone for DFine, as it fulfills the vision of extending our technology platform with a second procedure to serve the large population of patients suffering from painful spinal metastases,” said Kevin Mosher, chief executive officer, DFine. “We are encouraged by the support the Star System has received from the interventional radiology and oncology communities, as they realise the meaningful benefits t-RFA offers patients who previously had very limited treatment options.”

“We have been extremely satisfied with the results we have achieved with the Star System. Patients who were in severe pain have experienced significant pain relief and have been able to return to a better quality of life almost immediately following the procedure,” said Jerry Chang, interventional radiologist, Eisenhower Medical Center, California, USA. “Not only is it possible to achieve rapid pain relief with t-RFA, but it is also compatible with systemic therapies to treat the primary cancer, including both chemo and radiation therapies.”